scripps research institute
Recently Published Documents


TOTAL DOCUMENTS

50
(FIVE YEARS 2)

H-INDEX

2
(FIVE YEARS 0)

2021 ◽  
Vol 43 (4) ◽  
pp. 23-24

Abstract We are delighted to announce the 2021 recipients of the established IUPAC-Zhejiang NHU International Award for Advancements in Green Chemistry. We congratulate Gabriele Laudadio from the Scripps Research Institute, Lichen Liu from Tsinghua University, and Jingxiang Low from University of Science and Technology of China as the early career award winners, and David Milstein from the Weizmann Institute of Science, Israel for the experienced chemist award.



Synlett ◽  
2021 ◽  
Vol 32 (13) ◽  
pp. 1260-1261
Author(s):  
Xuefeng Jiang

Xuefeng Jiang is a professor at East China Normal University. He received his B.S. degree in 2003 from Northwest University (China). He then joined Professor Shengming Ma’s research group at the Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences, where he received his Ph.D. degree in 2008. From 2008 to 2011, Xuefeng worked as a postdoctoral researcher on the total synthesis of natural products in the research group of Professor K. C. Nicolaou at The Scripps Research Institute (TSRI). His independent research interests have focused on green organosulfur chemistry and methodology-­oriented total synthesis.



Synlett ◽  
2019 ◽  
Vol 30 (10) ◽  
pp. 1147-1148
Author(s):  
Yu Kawamata ◽  
Phil S. Baran

Yu Kawamata was born in Japan in 1988, and he completed his undergraduate education at Kyoto University. He obtained his master’s degree and his Ph.D. at the same university under the supervision of Professor Keiji Maruoka, and he undertook a short-term internship at The Scripps Research Institute working on natural product synthesis with Professor Phil S. Baran. Upon completion of his doctoral studies, he returned to the Baran laboratory as a research associate and currently is pursuing his postdoctoral studies on organic electrochemistry.Phil S. Baran was born in New Jersey in 1977 and completed his undergraduate education at New York University in 1997. After earning his Ph.D. at The Scripps Research Institute (TSRI) in 2001, he pursued postdoctoral studies at Harvard University until 2003, at which point he returned to TSRI to begin his independent career. He was promoted to the rank of professor in 2008 and is currently the Darlene Shiley Professor of Chemistry. The mission of his laboratory is to educate students at the intersection of fundamental organic chemistry and translational science.



2019 ◽  
Vol 139 (2) ◽  
pp. 221-228
Author(s):  
Akira Shigenaga


Synlett ◽  
2017 ◽  
Vol 28 (15) ◽  
pp. 1895-1896
Author(s):  
Lei Liu

Lei Liu received undergraduate training at the University of Science and Technology of China. He obtained his PhD degree at Columbia University in 2004 under the supervision of Prof. Ronald Breslow. He carried out post-doctoral studies at Scripps Research Institute from 2004 to 2007 in the laboratory of Prof. Chi-Huey Wong. He has been working at Tsinghua University since 2007. His research group studies chemical protein synthesis.



The Lancet ◽  
2015 ◽  
Vol 386 (10008) ◽  
pp. 2045
Author(s):  
Brian Owens


Nature ◽  
2015 ◽  
Vol 525 (7570) ◽  
pp. 438-438
Author(s):  
Erika Check Hayden


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 99-99
Author(s):  
Ranjeet Kumar Sinha ◽  
Laurent Burnier ◽  
Naveen Gupta ◽  
Xiao Xu ◽  
Sergey Kupriyanov ◽  
...  

Abstract Introduction: Thrombin (IIa) and activated protein C (APC) are serine proteases involved in coagulation and inflammatory responses that affect many cell types in the body. IIa employs the GPCR, protease activated receptor 1 (PAR1), to promote endothelial barrier disruption, vascular leakage, and inflammation. In contrast, APC requires PAR1 for its opposing actions to stabilize endothelial barriers and to provide anti-inflammatory and anti-apoptotic activities. Studies of murine in vivo injury models using PAR1 knockout mice show that APC requires PAR1 to reduce sepsis-induced mortality and to provide robust neuroprotection following ischemic stroke. Extensive in vitro studies support the hypothesis that IIa’s cleavage at R41 in PAR1 initiates its signaling. Although APC was long thought, paradoxically, to act also via cleavage at R41, we recently proposed that APC’s cleavage at R46 initiates its endothelial barrier-protective and cytoprotective signaling via biased signaling. Since PAR1 knock-out mice cannot provide mechanistic data for testing these hypotheses in vivo, mice carrying the point mutation of R41 to Q in PAR1 were generated to enable mechanistic studies to test whether or not IIa and APC require Arg41 for their PAR1-dependent effects. Methods: Using C57BL/6-derived embryonic stem cells and standard gene targeting methods, we prepared C57BL/6 mice carrying the PAR1 mutation of R41 to Q. IIa-induced and APC-induced signaling, detected as phosphorylation of ERK1/2 or Akt in Brain Microvascular Endothelial Cells (BECs), was quantified using immunoblotting. BECs were obtained from homozygous 41QQ-PAR1 mice and wild type 41RR-littermates. Endothelial barrier disruption of cultured BECs was assayed using Trans-Endothelial Resistance (TER) assays (iCelligence, Acea, San Diego). Mortality of wild type and 41QQ-PAR1 mutant mice that was caused by live E. coli-induced pneumonia and to endotoxin was determined using standard methods. The ability of a cytoprotective-selective murine APC mutant (5A-APC) to reduce mortality of E.coli-challenged wild type and homozygous mutant mice was determined. Results: Upon breeding of R41Q-PAR1 heterozygous mice, the progeny did not fit a Mendelian pattern and yielded only 14% rather than 25% homozygous 41QQ mice. This reduced yield of homozygous mutant mice was similar to the previously reported low yield of homozygous PAR1 knockout mice. Homozygous 41QQ-PAR1 mice showed normal protein expression in BECs for PAR1 and endothelial cell protein C receptor (EPCR) antigens. When BECs from homozygous mutant mice were compared to those from wild type littermates, the IIa-induced vascular disruption in TER assays was greatly reduced by the mutation. Intracellular Ca2+ release, a hallmark of IIa-induced signaling, was greatly impaired (>90%) in BECs from homozygous mutant mice compared to wild type controls. IIa-induced phosphorylation of ERK1/2 in BECs was also significantly reduced by the mutation whereas APC-induced phosphorylation of Akt was not significantly affected. In murine sepsis-induced mortality studies, homozygosity for the R41Q-PAR1 mutation conveyed considerable resistance to death induced by either E. coli pneumonia or endotoxin in female mice but not in male mice. Tests to determine whether 5A-APC rescued male mice from sepsis-induced lethality showed that homozygous 41QQ-PAR1 mice were entirely responsive to 5A-APC therapy because 5A-APC treatment reduced mortality from 50 % to 0 % (see Figure). Wild type control mice also showed a beneficial response with reduced mortality in response to 5A-APC therapy, as previously described. Conclusions: These studies show that mutation of Arg41 to Gln in murine PAR1 diminishes or eliminates signaling induced by IIa but not by APC. Moreover, the ability of cytoprotective-selective 5A-APC to reduce bacteria-induced septic mortality in 41QQ-PAR1 mutant mice provides strong in vivo proof-of-concept data for PAR1 activation caused by non-canonical cleavage by APC. In summary, the 41QQ-PAR1 mutant mouse provides a unique and powerful tool to define in vivo requirements for cleavage sites that enable PAR1 signaling activities induced by IIa, APC or other proteases. Figure 1 Figure 1. Disclosures Mosnier: The Scripps Research Institute : The Scripps Research Institute Patents & Royalties. Griffin:The Scripps Research Institute: The Scripps Research Institute Patents & Royalties.



Sign in / Sign up

Export Citation Format

Share Document